Mar 1 |
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
|
Feb 5 |
2seventy bio to Participate in Upcoming Investor Conferences
|
Feb 5 |
Bristol Myers, 2seventy bio to face FDA panel in March for Abecma decision
|
Feb 5 |
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
|
Jan 31 |
Leerink ups 2seventy to outperform, cites attractiveness as takeover target
|
Jan 31 |
Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
|
Jan 31 |
Crude Oil Down 2%; Alphabet Shares Fall After Q4 Results
|
Jan 30 |
2seventy stock rises as Regeneron acquires R&D assets
|
Jan 30 |
2seventy bio Announces New Strategic Path Forward
|
Jan 26 |
Bristol-Myers Squibb wins EU nod for expanded Abecma indication
|